Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by AQR Capital Management LLC

AQR Capital Management LLC grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 3.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,860 shares of the company’s stock after purchasing an additional 328 shares during the quarter. AQR Capital Management LLC’s holdings in Vaxcyte were worth $820,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Fifth Third Bancorp purchased a new position in Vaxcyte during the second quarter worth $35,000. Fidelis Capital Partners LLC purchased a new stake in Vaxcyte during the 1st quarter worth about $37,000. J.Safra Asset Management Corp raised its stake in Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after purchasing an additional 526 shares during the last quarter. Quest Partners LLC purchased a new position in Vaxcyte in the 2nd quarter valued at about $70,000. Finally, Covestor Ltd boosted its stake in shares of Vaxcyte by 451.7% during the 1st quarter. Covestor Ltd now owns 1,153 shares of the company’s stock worth $79,000 after purchasing an additional 944 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Up 2.5 %

PCVX opened at $114.42 on Friday. Vaxcyte, Inc. has a 52-week low of $44.20 and a 52-week high of $121.06. The company has a 50 day moving average of $98.39 and a two-hundred day moving average of $80.91. The company has a market cap of $12.77 billion, a P/E ratio of -24.45 and a beta of 0.99.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same period in the previous year, the company posted ($0.70) earnings per share. Research analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Leerink Partners increased their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group lifted their price target on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Needham & Company LLC increased their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $147.50.

Insider Buying and Selling

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $109.27, for a total transaction of $546,350.00. Following the completion of the sale, the senior vice president now owns 28,623 shares in the company, valued at $3,127,635.21. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $81.17, for a total transaction of $649,360.00. Following the sale, the chief financial officer now directly owns 96,720 shares of the company’s stock, valued at approximately $7,850,762.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $109.27, for a total transaction of $546,350.00. Following the sale, the senior vice president now owns 28,623 shares of the company’s stock, valued at approximately $3,127,635.21. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 78,098 shares of company stock valued at $7,429,653 in the last quarter. Company insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.